Last mentioned: Feb 27, 2026
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Fiscal Milestone
ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
Trial Setback
Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
Commercial Launch
Daybue officially enters the U.S. market with strong initial uptake.
FDA Approval
Daybue (trofinetide) approved as the first treatment for Rett syndrome.
Daybue Approval
FDA approves Daybue as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
Alkami Technology reported strong Q4 2025 results, highlighting a significant shift toward cloud-native digital banking platforms among regional financial institutions. The company's performance, alongside ACADIA Pharmaceuticals' commercial growth, underscores a resilient market for specialized SaaS and high-margin healthcare solutions.
ACADIA Pharmaceuticals and Alkami Technology reported Q4 results that highlight divergent paths for mid-cap growth entities. While ACADIA focuses on the commercial scaling of its rare disease portfolio, Alkami is battling a significant stock correction despite beating revenue expectations.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.